What LeonaBio, Inc. does.

We are a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (“ALS”), with the goal of improving patients’ lives.

Following a review of potential therapeutic and business opportunities, we acquired rights to a promising late-stage asset, lasofoxifene, for the potential treatment of ESR1-mutated (“mESR1”) metastatic breast cancer in December 2025. This late-stage program has generated promising clinical data and we believe it represents a unique and exciting opportunity to diversify our pipeline. We believe this program fits well with our later-stage clinical development experience, and complements our in-house asset, ATH-1105, a Phase-2 ready program for the potential treatment of ALS.

The drug development landscape in both oncology and neuroscience is evolving rapidly, driven by breakthroughs in genetics, disease biology, and molecular pathway research. We are leveraging this scientific momentum to advance a pipeline of innovative, late-stage assets both internally developed and strategically in-licensed with the goal of accelerating their path to market and maximizing their clinical and commercial impact.

Revenue and profit, by fiscal year.

More on LONA.

• LeonaBio, Inc. summary
• LeonaBio, Inc. financial statements
• LeonaBio, Inc. key metrics
• LeonaBio, Inc. health scores and style box
• LeonaBio, Inc. earnings
• LeonaBio, Inc. dividends
• LeonaBio, Inc. valuation
• LeonaBio, Inc. ownership and insiders
• LeonaBio, Inc. peers

Figures from LeonaBio, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.